Tag: newswire

MIAMI, FL, June 13, 2026 (GLOBE NEWSWIRE) -- Dengan SpaceX (NASDAQ: SPCX) dijangka mula didagangkan di Nasdaq hari ini, Defiance ETFs mengesahkan bahawa Defiance Daily 2X Space ETF (Cboe: SPCL) akan menyasarkan pendedahan berleveraj harian 2X kepada saham biasa Kelas A SpaceX dalam portfolionya. Langkah ini menjadikan SPCL sebagai dana dagangan bursa (ETF) pertama dan satu-satunya di Amerika Syarikat yang mempunyai pendedahan 2X kepada SpaceX pada hari IPO. Pendedahan SpaceX dalam dana tersebut ditetapkan pada harga IPO sebanyak USD135 sesaham.

佛罗里达州迈阿密, June 13, 2026 (GLOBE NEWSWIRE) -- 随着 SpaceX (纳斯达克代码：SPCX) 预计今日在纳斯达克开始交易，Defiance ETFs 证实，旗下 Defiance Daily 2X Space ETF (芝加哥期权交易所代码：SPCL) 将寻求在其投资组合中对 SpaceX A 类普通股提供 2 倍每日杠杆风险敞口。这使得该基金成为 SpaceX 上市首日首个也是唯一一个提供 2 倍杠杆风险敞口的美国 ETF。该基金按照 135 美元的 IPO 发行价确定了对 SpaceX 的风险敞口。

BetOnline issues a USA press announcement focused on No Deposit Casino interest, highlighting casino access, promotional visibility, player support, and responsible participation.

DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.^® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per share of common stock (or pre-funded warrant in lieu thereof) and associated preferred investment options.

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio^®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. STGD1 affects an estimated 53,000 people in the U.S. alone, and there are currently no approved treatment options for the disease.

NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Futu Holdings Limited (“Futu” or the “Company”) (NASDAQ:FUTU) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.

Regenerative Resort in Belize Wins Worldwide Recognition

Washington is now buying pieces of American miners. A former Pentagon advisor explains what it could mean and his latest prediction.